Neurotoxicity: distinguish the types of evidence
Animal experiments, human MRI associations and claims of specific neuronal damage require separate interpretation. In 2004, White withdrew claims from his 1998 neurotoxicity text.
ClarifiedAccording to the 2026 audit · edition
Evidence and limitations
What was examined: Carliss and Tran examined different administration routes and endpoints in rats. Qiu compared MRI findings in people dependent on DXM and a control group. White’s response records withdrawal of his earlier conclusions.
Limits of the conclusion: Transferring animal pathology to humans requires evidence. MRI associations allow several explanations; Olney lesions in humans after DXM have not been established in the reviewed sources.
Sources: Carliss — oral DXM in rats Tran — cellular changes in rats White — withdrawal of neurotoxicity claims Qiu — MRI in DXM dependence
Historical paraphrase · FAQ 4.0 · 1997 · §6.3.1 The FAQ discusses reports of lasting impairment and their resemblance to descriptions of Olney lesions. White later strengthened these claims in a separate text.
This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.3.1 · NMDA Antagonist Neurotoxicity (Olney's Lesions)